Jessup Wealth Management Inc Takes $331,000 Position in Danaher Co. (NYSE:DHR)

Jessup Wealth Management Inc bought a new position in shares of Danaher Co. (NYSE:DHR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,190 shares of the conglomerate’s stock, valued at approximately $331,000.

Other institutional investors also recently bought and sold shares of the company. Bradley Foster & Sargent Inc. CT grew its position in shares of Danaher by 6.0% in the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 538,354 shares of the conglomerate’s stock valued at $124,543,000 after purchasing an additional 30,588 shares during the period. Georgetown University boosted its stake in shares of Danaher by 73.4% in the fourth quarter. Georgetown University now owns 36,738 shares of the conglomerate’s stock worth $8,499,000 after acquiring an additional 15,548 shares during the last quarter. Groupama Asset Managment acquired a new position in Danaher in the 4th quarter valued at $27,628,000. Price T Rowe Associates Inc. MD boosted its stake in Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Finally, Oracle Alpha Inc. acquired a new stake in shares of Danaher in the fourth quarter valued at about $348,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Up 2.0 %

Shares of Danaher stock traded up $5.28 on Friday, reaching $271.73. 464,546 shares of the company were exchanged, compared to its average volume of 2,720,533. The stock’s 50 day moving average price is $270.44 and its 200-day moving average price is $258.97. The company has a market cap of $196.25 billion, a P/E ratio of 47.33, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the firm posted $2.05 EPS. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. As a group, equities analysts forecast that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s payout ratio is currently 19.18%.

Analyst Ratings Changes

Several analysts recently issued reports on DHR shares. The Goldman Sachs Group upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Wells Fargo & Company began coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Stephens started coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price for the company. Finally, Stifel Nicolaus boosted their price target on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $282.12.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares in the company, valued at $11,501,145.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.